Elekta Receives CE Mark for Fraxion, Immobilization System Designed to Improve Accuracy and Precision in Cranial Cancer Treatments

CRAWLEY, England, January 19, 2011 /PRNewswire/ --

Elekta has received CE mark clearance for its Fraxion(TM) patient-specific cranial immobilization system. The Fraxion head frame helps ensure accuracy and precision in stereotactic radiation therapy of cancer targets in the brain and cranium. Elekta's Fraxion is the first to introduce an innovative system that integrates all proven cranial immobilization options in a single solution.

"The advantage of Fraxion head fixation is that it is a stereotactic system that can be used for nearly any patient," says Prof. Dr. Meinhard Nevinny-Stickel, a radiation oncologist in the Department of Therapeutic Radiology and Oncology, Medical University Innsbruck (Austria). "The patient can be immobilized with a thermoplastic mask, with the proven vacuum mouthpiece, or even a combination of both systems. Precise repositioning is possible with easily accessible adjustment screws -- which make it much easier to fixate the patient in the treatment room."

The partial and full head thermoplastic masks provide alternative immobilization options for non-invasive setup, without compromising accuracy. Combining the thermoplastic mask with the vacuum mouthpiece increases flexibility in setup options, allowing optimal setup based on the patient's needs.

Fraxion also features a target positioner, which provides accurate target localization for stereotactic planning, imaging and treatment.

To learn more, visit http://www.elekta.com/fraxion.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit http://www.elekta.com.